Trials / Completed
CompletedNCT01123876
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Veliparib | Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2010-05-14
- Last updated
- 2021-08-02
Locations
8 sites across 2 countries: United States, South Korea
Source: ClinicalTrials.gov record NCT01123876. Inclusion in this directory is not an endorsement.